|
|
 |
|
Viewing report
|
|
|
|
Cardiovascular Disease: Current Research, Devices and Drugs
Drug and Market Development Publishing, Nov 2004, Pages: 693
The total worldwide cardiovascular market is expected to show revenues of $91.2 billion in 2008, an increase of 6.9% compared with 2003.
CVD is the leading cause of death in most regions throughout the world. Cardiovascular drugs constitute the world's largest pharmaceutical sector, with annual global sales over $70 billion. It has become clear that CVD is an inflammatory disease, although what triggers the inflammation is still unknown. Consequently, diagnosis of CVD through inflammatory markers is an active area of research. Although several classes of anti-hypertensive drugs exist, there are still several treatment goals that remain to be achieved, such as better blood pressure control, greater protection against organ damage, and better tolerability. Several angiogenic and myogenic stem cell therapies are under investigation and promise in the long run to advance cardiac rehabilitation and even prevent heart failure. Despite the development of improved therapies, millions of Americans continue to live with life-threatening cardiovascular diseases. Recent breakthroughs, such as cell transplantation, suggest exciting directions that are likely to produce more effective therapies for the treatment of cardiovascular disease.
Scope
This Report analyzes the pathology and rationale behind CVD risk reduction through a review of recently discovered genetic influences as well as a review of comorbid risk factors. It provides valuable market insight into improving CVD clinical trial design, as well as a thorough overview of the expanding medical device market.
Market Opportunities
Risk factor management for CVD is an emerging market. Developing more effective ways of delivering pharmacological, nutritional, and preventative therapies are recognized as important targets that are under continual development. Aging populations and dietary and lifestyle induced disease processes ensure a growing need for cardiovascular devices. Reducing the costs for such devices by appropriately treating cardiovascular risk factors has become a major focus of the pharmaceutical and healthcare industries. Here are just some of the considerable market opportunities within the CVD Market:
- Increased use of cholesterol-controlling statins will cause prices to fall and generic brands to appear as knowledge of their benefits spread among general practitioners.
- Develop anti-glycosylation therapies to prevent the cross-linking that weakens aging heart muscle, and to reduce the diabetic risk factor.
- Create new vaccines to raise high density lipoprotein (HDL) levels, which help stave off heart disease.
- Develop new angiotensin receptor blockers to offer greater competition against ACE inhibitors
- Develop angiogenesis drugs such as VEGF (vascular endothelial growth factor) that will obviate the need for much bypass surgery by growing new arteries on damaged hearts.
Key Reasons to Buy
- Learn how identifying cardiovascular risk factors and treatment earlier will cause a decline in Cardiovascular Disease (CVD) through an in depth analysis of the underlying pathology and rationale of CVD risk reduction.
- Gain crucial market knowledge about recently discovered genetic influences affecting CVD through an extensive analysis of associated mutations, including current research and clinical trials completed in this area.
- Facilitate the development of improved combination therapies through an in-depth analysis of recently completed clinical trials
- Receive a thorough review of comormid risk factors such as diabetes and obesity through an examination of how such risk factors affect the incidence of CVD.
- Review the expanding medical devices market through an in-depth analysis of CVD diagnostics and devices as well as the current research in this market area.
- Gain valuable market insight and improve CVD clinical design by reviewing extensive technical evidence, statistical expositions, case studies, and interviews relevant to CVD and CVD risk reduction.
- Look inside 40 companies active in the CVD market including their strategic alliances, products and pipelines, financial status, and more.
Customers who bought this item also bought
Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices
Cardiovascular Drug Delivery - Technologies, Markets and Companies
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Cardiovascular Disease Diagnostics - Global Strategic Business Report
The Cardiovascular Disorders Market Outlook to 2012
Cardiovascular Drug Discoveries 2008
Joint British Societies’ Guidelines on Prevention of CVD in Clinical Practice (JBS 2)
Cardiovascular Disease Diagnostics - A World Market Intelligence Report
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease
The 2009 Report on Cardiovascular Disease (CVD) Diagnostics: World Market Segmentation by City
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
|
|
|
|
